OmniAb, Inc. (NASDAQ:OABI) CFO Kurt A. Gustafson Sells 15,526 Shares of Stock

OmniAb, Inc. (NASDAQ:OABI) CFO Kurt A. Gustafson sold 15,526 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $50,304.24. Following the completion of the transaction, the chief financial officer now directly owns 212,720 shares in the company, valued at $689,212.80. This trade represents a 6.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

OmniAb Trading Down 0.6 %

Shares of OmniAb stock opened at $3.20 on Thursday. The company has a fifty day moving average price of $3.68 and a 200 day moving average price of $4.06. OmniAb, Inc. has a twelve month low of $3.16 and a twelve month high of $6.55. The stock has a market cap of $451.90 million, a price-to-earnings ratio of -5.16 and a beta of -0.10.

Wall Street Analyst Weigh In

Several brokerages have commented on OABI. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of OmniAb in a research note on Thursday, November 14th. Benchmark reissued a “buy” rating and set a $8.00 target price on shares of OmniAb in a research report on Thursday, November 14th.

Institutional Investors Weigh In On OmniAb

Institutional investors and hedge funds have recently modified their holdings of the stock. CWC Advisors LLC. purchased a new stake in shares of OmniAb during the 3rd quarter valued at about $54,000. Walleye Capital LLC acquired a new stake in OmniAb in the third quarter valued at approximately $61,000. Intech Investment Management LLC purchased a new stake in shares of OmniAb during the third quarter valued at approximately $70,000. China Universal Asset Management Co. Ltd. lifted its position in shares of OmniAb by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock worth $96,000 after purchasing an additional 8,909 shares in the last quarter. Finally, Palumbo Wealth Management LLC lifted its position in shares of OmniAb by 12.5% during the third quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock worth $104,000 after purchasing an additional 2,744 shares in the last quarter. Hedge funds and other institutional investors own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.